Sign up to save your data!
Some tips to help get started:
Processing...
There are 397 active trials for advanced/metastatic other solid tumor. Click on a trial to see more information. Note that this list also includes some trials that are only for specific cancer types like lung cancer. To see trials customized to a patient, please select a patient above.
397 trials meet filter criteria.
Sort by:
HealthScout AI summary: This trial is designed for adult patients with EGFR-positive advanced solid tumors that have progressed after systemic therapy, focusing on assessing the safety and optimal dosing of the investigational drug DK210, an EGFR-targeting agent, administered alone or with standard therapies.
ClinicalTrials.gov ID: NCT05704985
HealthScout AI summary: This trial involves adult patients with locally advanced or metastatic solid tumors lacking curative options and tests T-Plex, an autologous T cell therapy engineered to target specific peptide/HLA antigens like MAGE-A1 and HPV16 E7, administered alone or with lymphodepleting chemotherapy. The goal is to assess its safety, feasibility, and initial effectiveness in selectively targeting tumor cells expressing these antigens.
ClinicalTrials.gov ID: NCT05973487
HealthScout AI summary: This trial targets patients with metastatic solid cancers who have failed standard treatments, using autologous T-cells engineered to express T-cell receptors against neoantigens. It investigates the efficacy of these T-cells alone or combined with pembrolizumab, a PD-1 inhibitor, in reducing tumor size.
ClinicalTrials.gov ID: NCT03412877
HealthScout AI summary: This trial targets patients aged 18 and older with recurrent or metastatic non-small cell lung cancer who have failed prior chemotherapy and PD-1/PD-L1 therapies, testing the safety and efficacy of PBF-1129, an adenosine A2B receptor antagonist, combined with nivolumab, a PD-1 inhibitor.
ClinicalTrials.gov ID: NCT05234307
HealthScout AI summary: This trial evaluates FMC-376, a dual inhibitor of active and inactive KRAS G12C mutations, in patients with locally advanced unresectable or metastatic solid tumors who have progressed after or are intolerant to standard therapies. Eligible patients must have an ECOG performance status of 0 or 1, and the study includes dose escalation and expansion phases to assess safety, pharmacokinetics, and clinical activity.
ClinicalTrials.gov ID: NCT06244771
HealthScout AI summary: This trial involves patients with advanced or metastatic solid tumors with KRAS mutations or amplifications, assessing the investigational drug BGB-53038, a pan-KRAS inhibitor, both alone and in combination with the anti-PD-1 antibody tislelizumab and anti-EGFR antibody cetuximab.
ClinicalTrials.gov ID: NCT06585488
HealthScout AI summary: The trial investigates BGB-43395, a CDK4 inhibitor, alone or with fulvestrant or letrozole in patients with metastatic HR+/HER2- breast cancer and other advanced solid tumors reliant on CDK4, who are refractory or intolerant to standard therapies.
ClinicalTrials.gov ID: NCT06120283
HealthScout AI summary: The trial involves adult patients with locally advanced or metastatic NSCLC featuring EGFR mutations, specifically those resistant to third-generation EGFR TKIs like osimertinib due to C797X mutations but without T790M mutations, testing the safety and efficacy of STX-241, a fourth-generation EGFR TKI designed for resistance mutations.
ClinicalTrials.gov ID: NCT06567015
HealthScout AI summary: The trial involves patients with advanced, unresectable, or metastatic solid tumors who have exhausted standard therapies, testing VET3-TGI, an investigational oncolytic virus designed to target and destroy cancer cells, administered intratumorally or intravenously alone, and in combination with pembrolizumab, a PD-1 inhibitor.
ClinicalTrials.gov ID: NCT06444815
HealthScout AI summary: The trial involves adult patients with advanced or metastatic solid tumors, including breast, non-small cell lung, gastric, gastroesophageal, and colorectal cancers, receiving DM001, a bispecific antibody-drug conjugate targeting TROP2 and EGFR. The treatment seeks to establish dose tolerability and safety while employing a dual-targeting approach linking an antibody to a topoisomerase I inhibitor to enhance efficacy and reduce resistance.
ClinicalTrials.gov ID: NCT06475937
